CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
Zacks
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2
CEO Samarth Kulkarni said the second quarter showed strong progress and that the company enters the second half “well positioned, with a number of important milestones ahead across our pipeline.”
Stocktwits
ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
Zoetis heads into Q2 earnings with companion animal products and international growth in focus as U.S. competition and Librela concerns weigh.
Zacks
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
Key Points CRISPR Therapeutics recently won a key label expansion...
Nasdaq News: Markets
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.
Zacks
3 Stocks With the Most Upside by the End of 2026
Key PointsAfter a long wait, revenue should soon start flowing for gene-editing drugmaker CRISPR Therapeutics...
Nasdaq News: Markets
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.